* SRA International announced the sale of its e-mail surveillance unit, Assentor Solutions, to iLumin Software Services, saying it doesn't fit into its core government-contracting business. Terms of the deal, which closed Friday, were not disclosed. Fairfax-based SRA developed software that screens e-mail, including checking for profanity or stock hyping, five years ago. The unit reported $4 million in revenue last year and is profitable, an SRA spokesman said. The company doesn't expect any layoffs among the 18 to 20 employees in the division.

* Savvis Communications, a Herndon company that provides virtual private networks and Internet services, lost $15.8 million (24 cents per share) in the three months ended Sept. 30, compared with a loss of a $81.4 million (89 cents) in the same period of last year. The company's third-quarter revenue fell to $56.7 million from $58.4 million. The company said it raised $22.6 million in equity financing during the quarter and ended the period with $44.1 million in cash and cash equivalents. Shares of Savvis closed unchanged at 33 cents.

* Pacel, a Manassas company that provides human resource management services, completed its acquisition of Dallas-based BeneCorp Business Services. Terms of the acquisition, originally announced earlier this month, were not disclosed.

* Optimus, a Silver Spring government contractor, announced that Terence Fong will take over the position of president from founder Eric Adolphe, who will remain chief executive. Fong, formerly an executive with Lockheed Martin, will take control of the day-to-day management of the company.

* OCG Ventures, a Columbia venture capital firm formerly known as Optical Capital Group, named Scott Widham a partner. Widham was the founder and managing general partner of Clayton Capital. Widham plans to split time between Columbia and St. Louis.

* Neuralstem, a Gaithersburg biotechnology firm, said it reached an agreement with In Vitro Technologies of Baltimore that allows the two companies to jointly produce and market neurons derived from human neural stem cells to drug-discovery companies. Under the agreement, Neuralstem will produce and ship the neurons, while In Vitro will market and sell the products.

Compiled from reports by Washington Post staff writers, washingtonpost.com and Dow Jones News Service